Is SRZN or WVE more profitable?

WAVE Life Sciences has a net margin of -255.70% compared to Surrozen's net margin of -4,810.50%. WAVE Life Sciences' return on equity of -56.76% beat Surrozen's return on equity. Company Net Margins Return on Equity Return on Assets Surrozen -4,810.50% -4,055.04% -154.08% WAVE Life Sciences -255.70% -56.76% -42.80%

Does the media refer more to SRZN or WVE?

In the previous week, WAVE Life Sciences had 1 more articles in the media than Surrozen. MarketBeat recorded 2 mentions for WAVE Life Sciences and 1 mentions for Surrozen. Surrozen's average media sentiment score of 1.77 beat WAVE Life Sciences' score of 0.50 indicating that Surrozen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SRZN or SVRA more profitable?

Savara has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Savara's return on equity of -87.19% beat Surrozen's return on equity. Company Net Margins Return on Equity Return on Assets Surrozen -4,810.50% -4,055.04% -154.08% Savara N/A -87.19% -66.42%

Which has better valuation and earnings, SRZN or CVAC?

CureVac has higher revenue and earnings than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Surrozen $7.49M 39.36 -$242.03M -$37.59 N/A CureVac $70.74M 14.78 $175.50M $0.72 6.47

Is SRZN or CVAC more profitable?

CureVac has a net margin of 199.92% compared to Surrozen's net margin of -4,810.50%. CureVac's return on equity of -23.03% beat Surrozen's return on equity. Company Net Margins Return on Equity Return on Assets Surrozen -4,810.50% -4,055.04% -154.08% CureVac 199.92% -23.03% -19.09%

Does the media favor SRZN or CRVS?

In the previous week, Corvus Pharmaceuticals had 1 more articles in the media than Surrozen. MarketBeat recorded 2 mentions for Corvus Pharmaceuticals and 1 mentions for Surrozen. Surrozen's average media sentiment score of 1.77 beat Corvus Pharmaceuticals' score of 1.11 indicating that Surrozen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Surrozen (SRZN) Competitors

$25.40 +0.55 (+2.19%)

As of 03:11 PM Eastern

Compare

SRZN vs. WVE, SVRA, COLL, CVAC, and CRVS

Should you buy Surrozen stock or one of its competitors? MarketBeat compares Surrozen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Surrozen include WAVE Life Sciences (WVE), Savara (SVRA), Collegium Pharmaceutical (COLL), CureVac (CVAC), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry.

How does Surrozen compare to WAVE Life Sciences?

Surrozen (NASDAQ:SRZN) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

WAVE Life Sciences has a net margin of -255.70% compared to Surrozen's net margin of -4,810.50%. WAVE Life Sciences' return on equity of -56.76% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	-4,055.04%	-154.08%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Surrozen has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, meaning that its share price is 233% less volatile than the broader market.

WAVE Life Sciences has higher revenue and earnings than Surrozen. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$7.49M	39.36	-$242.03M	-$37.59	N/A
WAVE Life Sciences	$42.73M	27.04	-$204.38M	-$1.06	N/A

In the previous week, WAVE Life Sciences had 1 more articles in the media than Surrozen. MarketBeat recorded 2 mentions for WAVE Life Sciences and 1 mentions for Surrozen. Surrozen's average media sentiment score of 1.77 beat WAVE Life Sciences' score of 0.50 indicating that Surrozen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Surrozen currently has a consensus price target of $42.00, suggesting a potential upside of 65.32%. WAVE Life Sciences has a consensus price target of $26.41, suggesting a potential upside of 339.83%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Summary

WAVE Life Sciences beats Surrozen on 11 of the 17 factors compared between the two stocks.

How does Surrozen compare to Savara?

Surrozen (NASDAQ:SRZN) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Savara has lower revenue, but higher earnings than Surrozen. Savara is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$7.49M	39.36	-$242.03M	-$37.59	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Comparatively, 5.3% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Savara has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Savara's return on equity of -87.19% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	-4,055.04%	-154.08%
Savara	N/A	-87.19%	-66.42%

Surrozen has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Savara has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

Surrozen presently has a consensus price target of $42.00, suggesting a potential upside of 65.32%. Savara has a consensus price target of $10.14, suggesting a potential upside of 73.83%. Given Savara's stronger consensus rating and higher probable upside, analysts plainly believe Savara is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Surrozen had 1 more articles in the media than Savara. MarketBeat recorded 1 mentions for Surrozen and 0 mentions for Savara. Surrozen's average media sentiment score of 1.77 beat Savara's score of 0.00 indicating that Surrozen is being referred to more favorably in the media.

Company	Overall Sentiment
Surrozen	Very Positive
Savara	Neutral

Summary

Savara beats Surrozen on 9 of the 15 factors compared between the two stocks.

How does Surrozen compare to Collegium Pharmaceutical?

Surrozen (NASDAQ:SRZN) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

Collegium Pharmaceutical has a net margin of 9.41% compared to Surrozen's net margin of -4,810.50%. Collegium Pharmaceutical's return on equity of 95.18% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	-4,055.04%	-154.08%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

Collegium Pharmaceutical has higher revenue and earnings than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$7.49M	39.36	-$242.03M	-$37.59	N/A
Collegium Pharmaceutical	$780.57M	1.49	$62.87M	$2.04	17.56

Surrozen has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Surrozen currently has a consensus price target of $42.00, indicating a potential upside of 65.32%. Collegium Pharmaceutical has a consensus price target of $57.50, indicating a potential upside of 60.55%. Given Surrozen's higher possible upside, analysts clearly believe Surrozen is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Surrozen had 1 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 1 mentions for Surrozen and 0 mentions for Collegium Pharmaceutical. Surrozen's average media sentiment score of 1.77 beat Collegium Pharmaceutical's score of 1.50 indicating that Surrozen is being referred to more favorably in the media.

Company	Overall Sentiment
Surrozen	Very Positive
Collegium Pharmaceutical	Very Positive

66.6% of Surrozen shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Collegium Pharmaceutical beats Surrozen on 9 of the 15 factors compared between the two stocks.

How does Surrozen compare to CureVac?

Surrozen (NASDAQ:SRZN) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

CureVac has higher revenue and earnings than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$7.49M	39.36	-$242.03M	-$37.59	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

In the previous week, Surrozen had 1 more articles in the media than CureVac. MarketBeat recorded 1 mentions for Surrozen and 0 mentions for CureVac. Surrozen's average media sentiment score of 1.77 beat CureVac's score of 0.00 indicating that Surrozen is being referred to more favorably in the media.

Company	Overall Sentiment
Surrozen	Very Positive
CureVac	Neutral

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Surrozen currently has a consensus price target of $42.00, indicating a potential upside of 65.32%. CureVac has a consensus price target of $5.50, indicating a potential upside of 18.03%. Given Surrozen's stronger consensus rating and higher possible upside, analysts clearly believe Surrozen is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
CureVac	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Surrozen has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

CureVac has a net margin of 199.92% compared to Surrozen's net margin of -4,810.50%. CureVac's return on equity of -23.03% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	-4,055.04%	-154.08%
CureVac	199.92%	-23.03%	-19.09%

Summary

Surrozen beats CureVac on 9 of the 17 factors compared between the two stocks.

How does Surrozen compare to Corvus Pharmaceuticals?

Surrozen (NASDAQ:SRZN) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Corvus Pharmaceuticals has lower revenue, but higher earnings than Surrozen. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$7.49M	39.36	-$242.03M	-$37.59	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

Corvus Pharmaceuticals has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Corvus Pharmaceuticals' return on equity of -38.92% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	-4,055.04%	-154.08%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Surrozen has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

In the previous week, Corvus Pharmaceuticals had 1 more articles in the media than Surrozen. MarketBeat recorded 2 mentions for Corvus Pharmaceuticals and 1 mentions for Surrozen. Surrozen's average media sentiment score of 1.77 beat Corvus Pharmaceuticals' score of 1.11 indicating that Surrozen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Surrozen currently has a consensus price target of $42.00, indicating a potential upside of 65.32%. Corvus Pharmaceuticals has a consensus price target of $33.33, indicating a potential upside of 157.60%. Given Corvus Pharmaceuticals' higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Corvus Pharmaceuticals beats Surrozen on 9 of the 16 factors compared between the two stocks.

Get Surrozen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRZN vs. The Competition

Export

Metric	Surrozen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$294.96M	$3.00B	$6.57B	$12.22B
Dividend Yield	N/A	1.80%	2.69%	5.82%
P/E Ratio	-0.68	18.63	25.17	24.00
Price / Sales	39.36	478.41	554.19	120.01
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	-1.32	4.15	10.79	6.44
Net Income	-$242.03M	$64.45M	$3.56B	$337.14M
7 Day Performance	5.68%	1.68%	1.55%	-0.36%
1 Month Performance	-3.66%	1.26%	0.98%	0.61%
1 Year Performance	185.77%	24.78%	30.72%	27.86%

Surrozen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRZN Surrozen	3.8076 of 5 stars	$25.41 +2.2%	$42.00 +65.3%	+175.6%	$294.96M	$7.49M	N/A	80	Positive News
WVE WAVE Life Sciences	2.7348 of 5 stars	$6.03 +5.0%	$26.41 +338.4%	-13.2%	$1.16B	$71.80M	N/A	240
SVRA Savara	1.7008 of 5 stars	$5.48 +3.3%	$10.14 +85.3%	+167.6%	$1.12B	N/A	N/A	20
COLL Collegium Pharmaceutical	3.0241 of 5 stars	$34.35 -0.9%	$57.50 +67.4%	+15.9%	$1.11B	$796.33M	16.84	210	News Coverage Positive News Gap Down
CVAC CureVac	N/A	$4.66 flat	$5.50 +18.0%	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRZN) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Surrozen (SRZN) Competitors

SRZN vs. WVE, SVRA, COLL, CVAC, and CRVS

How does Surrozen compare to WAVE Life Sciences?

Summary

How does Surrozen compare to Savara?

Summary

How does Surrozen compare to Collegium Pharmaceutical?

Summary

How does Surrozen compare to CureVac?

Summary

How does Surrozen compare to Corvus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN vs. The Competition

Surrozen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Surrozen (SRZN) Competitors

SRZN vs. WVE, SVRA, COLL, CVAC, and CRVS

How does Surrozen compare to WAVE Life Sciences?

Is SRZN or WVE more profitable?

Which has more risk and volatility, SRZN or WVE?

Which has stronger earnings and valuation, SRZN or WVE?

Does the media refer more to SRZN or WVE?

Do institutionals and insiders hold more shares of SRZN or WVE?

Do analysts prefer SRZN or WVE?

Summary

How does Surrozen compare to Savara?

Which has stronger valuation and earnings, SRZN or SVRA?

Do institutionals and insiders have more ownership in SRZN or SVRA?

Is SRZN or SVRA more profitable?

Which has more volatility & risk, SRZN or SVRA?

Do analysts rate SRZN or SVRA?

Does the media favor SRZN or SVRA?

Summary

How does Surrozen compare to Collegium Pharmaceutical?

Is SRZN or COLL more profitable?

Which has stronger valuation & earnings, SRZN or COLL?

Which has more volatility & risk, SRZN or COLL?

Do analysts rate SRZN or COLL?

Does the media refer more to SRZN or COLL?

Do insiders and institutionals believe in SRZN or COLL?

Summary

How does Surrozen compare to CureVac?

Which has better valuation and earnings, SRZN or CVAC?

Does the media favor SRZN or CVAC?

Do insiders & institutionals have more ownership in SRZN or CVAC?

Do analysts prefer SRZN or CVAC?

Which has more risk and volatility, SRZN or CVAC?

Is SRZN or CVAC more profitable?

Summary

How does Surrozen compare to Corvus Pharmaceuticals?

Which has higher valuation and earnings, SRZN or CRVS?

Is SRZN or CRVS more profitable?

Do insiders & institutionals have more ownership in SRZN or CRVS?

Which has more volatility and risk, SRZN or CRVS?

Does the media favor SRZN or CRVS?

Do analysts recommend SRZN or CRVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN vs. The Competition

Surrozen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools